Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer

The efficacy and safety of naldemedine (a peripherally acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase III, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary end po...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2018-06, Vol.29 (6), p.1461-1467
Hauptverfasser:	Katakami, N., Harada, T., Murata, T., Shinozaki, K., Tsutsumi, M., Yokota, T., Arai, M., Tada, Y., Narabayashi, M., Boku, N.
Format:	Artikel
Sprache:	eng
Schlagworte:	bowel movement cancer naldemedine opioid-induced constipation Original peripherally acting μ-opioid receptor antagonist (PAMORA) quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!